Home News Letter from our CEO Letter from our CEO: 2023 – Year of innovation

With the first month of 2023 already behind us, it is time for me to reach out and wish you and your families a very good year, abundant with happiness, success, and positive experiences. We at GALVmed are excited about the opportunities and adventures this New Year holds in store and look forward to a myriad of deliveries and innovation.

On the delivery side, we are excited by the reports from our Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL) programme, where all VITAL partner companies, ably supported by a new market potential model, have provided their launch plans for the large ruminant, small ruminant, and poultry combination vaccines which are scheduled for registration in 2023 & 2024. In the meantime, all other projects, including setting up distribution networks in West-Africa and South Asia, as well as the expansion of hatchery vaccination (PREVENT) and the project evaluating and managing tick-resistance in sub-Saharan Africa (MAHABA) are progressing very well and will be nearing completion within the next two years.

For this reason, GALVmed’s main focus this year will be to propose a new, integrated project portfolio for Research & Development, Enabling Environment and Commercial Development in line with our GALVmed2030 Strategy. It will allow for significant progress in the veterinary access to medicines in sub-Saharan Africa and the Indian subcontinent. This remains a hugely ambitious undertaking in a highly complex and fragmented business environment.

We are also embarking on a new technologically driven market development programme. We are going to test three prototypes developed last year for market intelligence, veterinary drug supply chain management and telehealth & e-commerce. We will focus on connecting farmers, suppliers, veterinarians, and other public and private supply and value chain players through digitisation. Not everything we will learn will be to our liking, but we intend to turn all feedback into better innovation. We will continue and extend the industry engagement exercise launched in 2022 to increase our understanding of the needs and priorities of other important stakeholders in the livestock value chain and explore synergies for collaboration. And finally, we will attempt to lay the groundwork for a new, major Last-Mile livestock vaccine initiative, which is expected to 1) close the remaining access gaps for several livestock vaccines, 2) improve supply security and the quality of vaccines, and 3) connect key stakeholders and build trust in vaccines among farmers in Sub-Saharan Africa & South Asia.

As in previous years, we cordially invite our partners and stakeholders to support, inspire, and assist GALVmed in our purpose of transforming the animal health landscape and small-scale producers lives for the better. 2023 will be another very busy and exciting year for us.”.

Dr Carolin Schumacher
Chief Executive Officer